The use of high-sensitivity assays for C-reactive protein in clinical practice

[1]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[2]  淳一 佐々木.  Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[3]  C. Meisinger,et al.  Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. , 2008, Clinical chemistry.

[4]  Georg Endler,et al.  C-reactive protein and all-cause mortality in a large hospital-based cohort. , 2008, Clinical chemistry.

[5]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[6]  M. Bissell.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery DiseaseSabatine MS, for the PEACE Investigators (Harvard Med School; et al) Circulation 1 , 2008 .

[7]  D. Lawlor,et al.  A systematic review of the association between circulating concentrations of C reactive protein and cancer , 2007, Journal of Epidemiology and Community Health.

[8]  G. Lowe,et al.  Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study , 2007, Circulation.

[9]  L. Chambless,et al.  Sex Differences in the Prediction of Type 2 Diabetes by Inflammatory Markers , 2007, Diabetes Care.

[10]  W. Hoy,et al.  C-reactive protein and the risk of developing type 2 diabetes in Aboriginal Australians. , 2007, Diabetes research and clinical practice.

[11]  M. Pfeffer,et al.  Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[12]  P. Macfarlane,et al.  C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) , 2007, Circulation.

[13]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[14]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[15]  M. Hamer.  The relative influences of fitness and fatness on inflammatory factors. , 2007, Preventive medicine.

[16]  Nancy R. Cook,et al.  Cook Prediction Use and Misuse of the Receiver Operating Characteristic Curve in Risk , 2007 .

[17]  D. Levy,et al.  Multiple biomarkers for the prediction of first major cardiovascular events and death. , 2006, The New England journal of medicine.

[18]  L. Chambless,et al.  Increased Concentrations of C-Reactive Protein and IL-6 but not IL-18 Are Independently Associated With Incident Coronary Events in Middle-Aged Men and Women: Results From the MONICA/KORA Augsburg Case–Cohort Study, 1984–2002 , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[19]  P. Libby,et al.  Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice , 2006 .

[20]  R. D'Agostino,et al.  Abstract 4070: Increased CRP and Long Term Risk for Cardiovascular Events in Middle Age Men and Women , 2006 .

[21]  A. Hofman,et al.  High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study , 2006, Circulation.

[22]  R. Peters,et al.  C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. , 2006, Atherosclerosis.

[23]  J. Mega,et al.  Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy , 2006, Journal of Thrombosis and Thrombolysis.

[24]  P. Ridker,et al.  C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference? , 2006, Circulation.

[25]  Amy Shui,et al.  Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.

[26]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[27]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[28]  Paul M Ridker,et al.  C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. , 2006, Journal of the American College of Cardiology.

[29]  P. Ridker,et al.  Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. , 2006, JAMA.

[30]  K. Sung.  Seasonal variation of C-reactive protein in apparently healthy Koreans. , 2006, International journal of cardiology.

[31]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[32]  S. Ibayashi,et al.  C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population: The Hisayama Study , 2006, Stroke.

[33]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[34]  M. Pencina,et al.  C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. , 2005, Archives of internal medicine.

[35]  E. Boerwinkle,et al.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. , 2005, Archives of internal medicine.

[36]  M. Kubo,et al.  Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. , 2005, Diabetes care.

[37]  P. Whincup,et al.  Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. , 2005, European heart journal.

[38]  L. Niskanen,et al.  C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. , 2005, European heart journal.

[39]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[40]  J. Polak,et al.  C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study , 2005, Circulation.

[41]  P. Hildebrandt,et al.  N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. , 2005, JAMA.

[42]  P. Whincup,et al.  The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. , 2005, Atherosclerosis.

[43]  J. Strong,et al.  Elevated Serum C-Reactive Protein Levels and Advanced Atherosclerosis in Youth , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[44]  F. Mach,et al.  Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[45]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[46]  Mitchell H Gail,et al.  On criteria for evaluating models of absolute risk. , 2005, Biostatistics.

[47]  J. Farmer.  Reversal of atherosclerosis with aggressive lipid lowering. , 2005, Current atherosclerosis reports.

[48]  N. Wong,et al.  Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. , 2005, Diabetes care.

[49]  E. Tuzcu,et al.  Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease , 2005 .

[50]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[51]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[52]  G. Lowe,et al.  C-Reactive Protein, Fibrin D-Dimer, and Risk of Ischemic Heart Disease: The Caerphilly and Speedwell Studies , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[53]  G. Lowe,et al.  Interleukin-6, Fibrin D-Dimer, and Coagulation Factors VII and XIIa in Prediction of Coronary Heart Disease , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[54]  L. Niskanen,et al.  C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men , 2004, Diabetologia.

[55]  Paul M Ridker,et al.  Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? , 2004, Circulation.

[56]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[57]  A. Mokdad,et al.  The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. , 2004, Journal of the American College of Cardiology.

[58]  D. Berman,et al.  Implications of estimating coronary heart disease risk in the US population. , 2004, Journal of the American College of Cardiology.

[59]  P. Ridker,et al.  C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). , 2004, The American journal of cardiology.

[60]  N. Cook,et al.  Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores , 2004, Circulation.

[61]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[62]  C. Meisinger,et al.  C-Reactive Protein Modulates Risk Prediction Based on the Framingham Score: Implications for Future Risk Assessment: Results From a Large Cohort Study in Southern Germany , 2004, Circulation.

[63]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[64]  Heejung Bang,et al.  Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study , 2004, Circulation.

[65]  S. Rubin,et al.  Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.

[66]  P. Ridker.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. , 2003, Circulation.

[67]  Masamichi Okubo,et al.  Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. , 2003, Diabetes care.

[68]  A. Dyer,et al.  Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .

[69]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[70]  David M Herrington,et al.  C-Reactive Protein, Carotid Intima-Media Thickness, and Incidence of Ischemic Stroke in the Elderly: The Cardiovascular Health Study , 2003, Circulation.

[71]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[72]  A. Evans,et al.  C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[73]  A. Hofman,et al.  The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. , 2003, Archives of internal medicine.

[74]  P. Wilson,et al.  34th Bethesda Conference: Task force #1--Identification of coronary heart disease risk: is there a detection gap? , 2003, Journal of the American College of Cardiology.

[75]  Jiang He,et al.  Relationship between Cigarette Smoking and Novel Risk Factors for Cardiovascular Disease in the United States , 2003, Annals of Internal Medicine.

[76]  P. Ridker,et al.  Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. , 2003, The American journal of medicine.

[77]  Alessandro Pontillo,et al.  Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. , 2003, JAMA.

[78]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[79]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[80]  S. Cummings,et al.  The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. , 2003, The American journal of medicine.

[81]  Gary L Myers,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[82]  P. Ridker.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.

[83]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[84]  N. Sattar,et al.  Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. , 2002, Diabetes care.

[85]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[86]  J. Manson,et al.  Relation between markers of systemic vascular inflammation and smoking in women. , 2002, The American journal of cardiology.

[87]  Katsuhiko Yano,et al.  C-reactive protein and myocardial infarction. , 2002, Journal of clinical epidemiology.

[88]  N. Sattar,et al.  C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. , 2002, Diabetes.

[89]  P. Whincup,et al.  Physical Activity and Hemostatic and Inflammatory Variables in Elderly Men , 2002, Circulation.

[90]  Nader Rifai,et al.  Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide , 2002, Circulation.

[91]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[92]  W. Koenig,et al.  Lack of seasonal variation in C-reactive protein. , 2002, Clinical chemistry.

[93]  E. Poehlman,et al.  Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women , 2002, Circulation.

[94]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[95]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[96]  G. Dagenais,et al.  Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. , 2001, Archives of internal medicine.

[97]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[98]  L. Kuller,et al.  The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. , 2001, Diabetes.

[99]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[100]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[101]  Paul M. Ridker,et al.  Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[102]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[103]  R. Westendorp,et al.  C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[104]  F. Rosendaal,et al.  C‐reactive protein, cardiovascular risk factors and the association with myocardial infarction in men , 2000, Journal of internal medicine.

[105]  A. Siegbahn,et al.  Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.

[106]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[107]  E. Ford,et al.  Serum C-reactive protein and self-reported stroke: findings from the Third National Health and Nutrition Examination Survey. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[108]  L. Bouter,et al.  von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[109]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[110]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[111]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[112]  Enrique Sanchez-Delgado,et al.  Lifetime risk of developing coronary heart disease , 1999, The Lancet.

[113]  M. Pfeffer,et al.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[114]  E. Antman,et al.  C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .

[115]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[116]  E. Antman,et al.  C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.

[117]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[118]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[119]  R. Eckel.  Insulin resistance in atherosclerosis. , 1997, The American journal of clinical nutrition.

[120]  L. Kuller,et al.  Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. , 1996, American journal of epidemiology.

[121]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.